ClinicalTrials.gg
Not yet recruitingNCT06512363Updated Jul 22, 2024

A Study of Ramelteon in Chinese Patients With Chronic Insomnia

A Phase 3 interventional study of Ramelteon and Ramelteon placebo in Chronic Insomnia, sponsored by Nanjing Chia-tai Tianqing Pharmaceutical. Not yet recruiting. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-07-22.

Sponsored by Nanjing Chia-tai Tianqing Pharmaceutical (part of Sino Biopharmaceutical Limited) · Phase 3, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
280
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders — 1 open to participants now, 1 under way, 1 of them phase 3. ramelteon · Sleep Initiation and Maintenance Disorders.

Planned enrollment
11th of 36
280 · median 65
Started
2024
the only one that year
Phase 3
16 of 36
1 open now
Registered
36th of 36
by date
Lead sponsor
1 of 36
Nanjing Chia-tai Tianqing Pharmaceutical

Among the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, this one is the 11th largest by planned enrollment, is the only one that started in 2024, is one of 16 in phase 3, and was the 36th registered.

Sleep Initiation and Maintenance Disorders

2,732 studies on the registry are indexed under Sleep Initiation and Maintenance Disorders; 733 are open to participants now.

Browse Sleep Initiation and Maintenance Disorders studies →

Open to participants now

1 of the 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders is open now.

About ramelteon

ramelteon: first FDA approval 2005 (ROZEREM). What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 392 Sleep Initiation and Maintenance Disorders studies recruiting now, 155 (40%) set no upper age limit and 207 (53%) stop at 75 or younger; 59 take children under 18; 110 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies testing ramelteon in Sleep Initiation and Maintenance Disorders, or all of them as a file.
02

Study summary

The purpose of this study is to assess the efficacy and safety of Ramelteon in chinese patients with chronic insomnia.

Efficacy will be evaluated on objective and subjective sleep parameters.

03

Conditions studied

  • Chronic Insomnia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male or female aged ≥ 18 years old.
  • Chronic insomnia disorder diagnosed according to International Classification of Sleep Disorders, Third Edition, Text Revision (ICSD-3-TR) criteria.
  • Self-reported history of all the following on at least 3 nights per week within 4 weeks prior to screening: subjective sleep latency (sSL) greater than or equal to 30 minutes, and subjective total sleep time (sTST) less than or equal to 6.5 hours per night.
  • Meeting all the following sleep parameters on the 2 PSG nights during the run-in period: mean latency to persistent sleep (LPS) ≥ 20 min (with neither of the two nights \< 15 min), and mean wake after sleep onset (WASO) ≥ 30 min (with neither of the two nights \< 20 min).
  • Usual bedtime between 20:30 and 01:00, and regular time in bed between 6.5 and 9 h.
  • Insomnia Severity Index score≥15 at screening and on Day 1 of the treatment period.
  • Understand the study procedures and methods, voluntarily participate in this trial, and sign the .

Exclusion criteria

Exclusion Criteria:

  • Use of ramelteon within 30 days prior to screening.
  • Previous non-responders to melatonin receptor agonist therapy.
  • Known to ramelteon or related compounds, including melatonin.
  • Sleep schedule changes required by employment (e.g. shift worker), or has flown across greater than three time zones (mainland China is considered as 1 time zone) within 30 days prior to screening and during the study period; or special professionals who need to operate machinery during the study period, such as professional drivers, high-altitude operators, etc.
  • Participated in a weight loss program or has substantially altered their exercise routine within 30 days prior to screening and during the study period.
  • Previous history of nervous system disorders such as epilepsy, schizophrenia, bipolar mental disorder, neurodevelopmental retardation, and cognitive disorder, or previous history of other mental illness that may affect the safety of the subjects or interfere with the study assessments in the opinion of the investigator.
  • Previous history of other sleep disorders secondary to other diseases including moderate to severe obstructive sleep apne, circadian rhythm sleep disturbances, paroxysmal sleeping sickness, and restless legs syndrome.
  • Apnea-hypopnea index (AHI) and periodic limb movement index (PLMI) > 15 times/hour detected by PSG monitoring during the run-in period.
  • Have previous complex sleep behaviors, such as sleep driving, sleep eating, and sleep phone calls.
  • Hamilton Anxiety Scale (HAMA) score ≥ 14 and Hamilton Depression Scale (HAMD) score ≥ 18 at screening.
  • Have serious diseases of cardiovascular system, digestive system, respiratory system, urinary system, endocrine system, immune system, etc., which are not suitable for the study judged by the investigators.
  • or ALT > 3 × , and > 2 × ULN.
  • Patients with or syphilis infection.
  • Use of any hypnotics, antidepressants, antipsychotic drugs, anticholinergics, memory-enhancing drugs, antihistamines, centrally acting analgesics, centrally acting muscle relaxants, central nervous system stimulants, strong CYP1A2 inhibitors, strong CYP2C9 inhibitors, strong inhibitors, strong CYP inducers, or any other therapies for insomnia disorder within 1 week prior to the run-in period or within 5 half-lives of the product, whichever is longer.
  • Requirement of taking any prohibited medication during study period.
  • History of drug abuse within 1 year prior to screening, or positive urine drug screening.
  • History of alcohol abuse within 1 year prior to screening, or unwilling to follow alcohol restriction during the study period.
  • Regular daily consumption of excessive tea and coffee drinks, or unwilling to follow tea/coffee restriction during the study period.
  • History of smoking addiction or unwilling to follow tobacco restriction during the study period.
  • Participated in any other investigational study and taken any investigational drug within 1 month or 5 half-lives prior to screening, whichever is longer.
  • Pregnant or lactating women, or planning to have children or both men of and women of disagree to use ≥1 effective throughout the study and within 3 months after the end of the study.
  • MEQ-19 score ≤ 49.
  • Other conditions that are not considered appropriate by the investigator.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Reproductive potential

Able to have children. For women this usually means from the first period until menopause, unless permanently unable to through surgery; for men, unless permanently sterile. Read who the line is about — participants, women, men, or their partners.

Criteria about it usually ask for contraception during the study and for a time after it.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
280 participants (estimated)

Study arms

  • Experimental
    Ramelteon 8 mg QN

    Drug: Ramelteon

  • Placebo comparator
    Placebo

    Drug: Ramelteon placebo

Interventions

  • Ramelteon 8 mg, tablets, orally, once nightly for up to 5 weeks.

  • DrugRamelteon placebo

    Ramelteon placebo-matching tablets, orally, once nightly for up to 5 weeks.

06

What researchers measure

Primary outcomes

  1. Mean Latency to Persistent Sleep Assessed by Polysomnography

    Time frame: Week 1

Secondary outcomes

  1. Mean Latency to Persistent Sleep Assessed by Polysomnography

    Time frame: Week 5

  2. Total Sleep Time Assessed by Polysomnography

    Time frame: Weeks 1 and 5

  3. Sleep Efficiency Assessed by Polysomnography

    Time frame: Weeks 1 and 5

  4. Awake Time after Persistent Sleep Assessed by Polysomnography

    Time frame: Weeks 1 and 5

  5. Number of Awakenings after Persistent Sleep Assessed by Polysomnography

    Time frame: Weeks 1 and 5

  6. Subjective Sleep Latency Assessed by Sleep Diary Questionnaire

    Time frame: Weeks 1, 3 and 5

  7. Subjective Total Sleep Time Assessed by Sleep Diary Questionnaire

    Time frame: Weeks 1, 3 and 5

  8. Subjective Sleep Quality Assessed by Sleep Diary Questionnaire

    Time frame: Weeks 1, 3 and 5

  9. Subjective Awake Time Assessed by Sleep Diary Questionnaire

    Time frame: Weeks 1, 3 and 5

  10. Subjective Number of Awakenings Assessed by Sleep Diary Questionnaire

    Time frame: Weeks 1, 3 and 5

  11. Subjective Ease of Falling Back to Sleep Assessed by Sleep Diary Questionnaire

    Time frame: Weeks 1, 3 and 5

  12. Insomnia Severity Index Score Assessed by ISI Questionnaire

    Time frame: Weeks 3 and 5

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Aug 2024; primary completion for Dec 2026, 28 months later.

Of 29 industry-sponsored phase 3 interventional studies under Sleep Initiation and Maintenance Disorders, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 25. This study's planned 28 months is above that.

Counting every sponsor, half of 42 studies reached it within 19 months; a quarter within 15 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 9, 2024
First posted
Jul 22, 2024
StartEst.
Aug 2024
Primary completionEst.
Dec 2026
CompletionEst.
Dec 2026
Last update
Jul 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06512363
Responsible party
Sponsor
First posted
Jul 22, 2024
Start date
Aug 2024 (estimated)
Primary completion
Dec 2026 (estimated)
Completion
Dec 2026 (estimated)
Last update
Jul 22, 2024

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ramelteon

Start the discussion